Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance.
Several molecular assays to detect resistance to Rifampin, the Fluoroquinolones, and Aminoglycosides in Mycobacterium tuberculosis (M. tuberculosis) have been recently described. A systematic approach for comparing these assays in the laboratory is needed in order to determine the relative advantage of each assay and to decide which ones should be advanced to evaluation. We performed an analytic comparison of a Sloppy Molecular Beacon (SMB) melting temperature (Tm) assay and a Dual labeled probe (DLP) Tm assay. Both assays targeted the M. tuberculosis rpoB, gyrA, rrs genes and the eis promoter region. The sensitivity and specificity to detect mutations, analytic limit of detection (LOD) and the detection of heteroresistance were tested using a panel of 56 clinical DNA samples from drug resistant M. tuberculosis strains. Both SMB and DLP assays detected 29/29 (100%) samples with rpoB RRDR mutations and 3/3 (100%) samples with eis promoter mutations correctly. The SMB assay detected all 17/17 gyrA mutants and 22/22 rrs mutants, while the DLP assay detected 16/17 (94%) gyrA mutants and 12/22 (55%) rrs mutants. Both assays showed comparable LODs for detecting rpoB and eis mutations; however, the SMB assay LODs were at least two logs better for detecting wild type and mutants in gyrA and rrs targets. The SMB assay was also moderately better at detecting heteroresistance. In summary, both assays appeared to be promising methods to detect drug resistance associated mutations in M. tuberculosis; however, the relative advantage of each assay varied under each test condition.
Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Sandy S
SS
Roh
Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Laura E
LE
Smith
Department of Microbiology, International Tuberculosis Research Center, Changwon, Gyeongsang, Republic of Korea.
Jong Seok
JS
Lee
Tuberculosis Research Section, LCID, NIAID, NIH, Bethesda, MD, United States of America.
Laura E
LE
Via
Tuberculosis Research Section, LCID, NIAID, NIH, Bethesda, MD, United States of America.
Clifton E
CE
Barry
Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
David
D
Alland
Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Soumitesh
S
Chakravorty
D000617:Aminoglycosides / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology*; D004252:DNA Mutational Analysis; D004269:DNA, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D025202:Molecular Diagnostic Techniques; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics*; D016133:Polymerase Chain Reaction; D015203:Reproducibility of Results; D012293:Rifampin / Q000494:pharmacology; D012680:Sensitivity and Specificity; D013183:Sputum / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000382:microbiology*
D000617:Aminoglycosides; D000995:Antitubercular Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D012293:Rifampin